Peter Ciznar

Peter Ciznar

Auto-generated profile, based on publicly available information

Peter Ciznar

Department of Pediatrics, Faculty of Medicine Comenius University and Children's University Hospital, Bratislava, Slovakia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
BGBenjamin Gathmann
Benjamin Gathmann
NMNizar Mahlaoui
Nizar Mahlaoui
LGLaurence Gérard
Laurence Gérard
EOEric Oksenhendler
Eric Oksenhendler
KWKlaus Warnatz
Klaus Warnatz
BGBodo Grimbacher
Bodo Grimbacher

1 July 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
FCFrancesca Conti
Francesca Conti
SLSaul Oswaldo Lugo-Reyes
Saul Oswaldo Lugo-Reyes
LGLizbeth Blancas Galicia
Lizbeth Blancas Galicia
JHJianxin He
Jianxin He
GAGüzide Aksu
Güzide Aksu
JBJacinta Bustamante
Jacinta Bustamante

8 November 2023 in Nature
Verified
Journal Article
Open access
PDF file
TVTom Le Voyer
Tom Le Voyer
APAudrey Parent
Audrey Parent
XLXian Liu
Xian Liu
ACAxel Cederholm
Axel Cederholm
AGAdrian Gervais
Adrian Gervais
APAnne Puel
Anne Puel
Patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1) caused by autosomal recessive AIRE deficiency produce autoantibodies that neutralize type I interferons (IFNs)1,2, conferring a predisposition to life-threatening COVID-19 pneumonia3. Here we report that patients with autosomal recessive NIK or RELB deficiency, or a specific type of autosomal-dominant NF-κB2 deficiency, also have neutralizing autoantibodies against type I IFNs and are at higher risk of getting life-threatening COVID-19 pneumonia. In patients with autosomal-dominant NF-κB2 deficiency, these autoantibodies are found only in individuals who are heterozygous for variants associated with both transcription (p52 activity) loss of function (LOF) due to impaired p100 processing to generate p52, and regulatory (IκBδ activity) gain of function (GOF) due to the accumulation of unprocessed p100, therefore increasing the inhibitory activity of IκBδ (hereafter, p52LOF/IκBδGOF). By contrast, neutralizing autoantibodies against type I IFNs are not found in individuals who are heterozygous for NFKB2 variants causing haploinsufficiency of p100 and p52 (hereafter, p52LOF/IκBδLOF) or gain-of-function of p52 (hereafter, p52GOF/IκBδLOF). In contrast to patients with APS-1, patients with disorders of NIK, RELB or NF-κB2 have very few tissue-specific autoantibodies. However, their thymuses have an abnormal structure, with few AIRE-expressing medullary thymic epithelial cells. Human inborn errors of the alternative NF-κB pathway impair the development of AIRE-expressing medullary thymic epithelial cells, thereby underlying the production of autoantibodies against type I IFNs and predisposition to viral diseases.

24 March 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
Vivien BéziatVivien Béziat
Vivien Béziat
STSimon J. Tavernier
Simon J. Tavernier
YCYin-Huai Chen
Yin-Huai Chen
CMCindy S. Ma
Cindy S. Ma
MMMarie Materna
Marie Materna
APAnne Puel
Anne Puel
Autosomal dominant hyper-IgE syndrome (AD-HIES) is typically caused by dominant-negative (DN) STAT3 mutations. Patients suffer from cold staphylococcal lesions and mucocutaneous candidiasis, severe allergy, and skeletal abnormalities. We report 12 patients from 8 unrelated kindreds with AD-HIES due to DN IL6ST mutations. We identified seven different truncating mutations, one of which was recurrent. The mutant alleles encode GP130 receptors bearing the transmembrane domain but lacking both the recycling motif and all four STAT3-recruiting tyrosine residues. Upon overexpression, the mutant proteins accumulate at the cell surface and are loss of function and DN for cellular responses to IL-6, IL-11, LIF, and OSM. Moreover, the patients’ heterozygous leukocytes and fibroblasts respond poorly to IL-6 and IL-11. Consistently, patients with STAT3 and IL6ST mutations display infectious and allergic manifestations of IL-6R deficiency, and some of the skeletal abnormalities of IL-11R deficiency. DN STAT3 and IL6ST mutations thus appear to underlie clinical phenocopies through impairment of the IL-6 and IL-11 response pathways.

1 August 2015 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
BWBeata Wolska-Kuśnierz
Beata Wolska-Kuśnierz
HGHanna Gregorek
Hanna Gregorek
KCKrystyna Chrzanowska
Krystyna Chrzanowska
BPBarbara Piatosa
Barbara Piatosa
BPBarbara Pietrucha
Barbara Pietrucha
IDInborn Errors Working Party Of The Society For European Blood And Marrow Transplantation And The European Society For Immune Deficiencies
Inborn Errors Working Party Of The Society For European Blood And Marrow Transplantation And The European Society For Immune Deficiencies

13 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
TVTanja C. Vallée
Tanja C. Vallée
JGJannik S. Glasmacher
Jannik S. Glasmacher
HBHannes Buchner
Hannes Buchner
PAPeter D. Arkwright
Peter D. Arkwright
UBUta Behrends
Uta Behrends
MAMichael H. Albert
Michael H. Albert
Wiskott-Aldrich syndrome (WAS) is a multifaceted monogenic disorder with a broad disease spectrum and variable disease severity and a variety of treatment options including allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy (GT). No reliable biomarker exists to predict disease course and outcome for individual patients. A total of 577 patients with a WAS variant from 26 countries and a median follow-up of 8.9 years (range, 0.3-71.1), totaling 6118 patient-years, were included in this international retrospective study. Overall survival (OS) of the cohort (censored at HSCT or GT) was 82% (95% confidence interval, 78-87) at age 15 years and 70% (61-80) at 30 years. The type of variant was predictive of outcome: patients with a missense variant in exons 1 or 2 or with the intronic hot spot variant c.559+5G>A (class I variants) had a 15-year OS of 93% (89-98) and a 30-year OS of 91% (86-97), compared with 71% (62-81) and 48% (34-68) in patients with any other variant (class II; P < .0001). The cumulative incidence rates of disease-related complications such as severe bleeding (P = .007), life-threatening infection (P < .0001), and autoimmunity (P = .004) occurred significantly later in patients with a class I variant. The cumulative incidence of malignancy (P = .6) was not different between classes I and II. It confirms the spectrum of disease severity and quantifies the risk for specific disease-related complications. The class of the variant is a biomarker to predict the outcome for patients with WAS.